Responses
Other responses
Jump to comment:
- Published on: 29 April 2016
- Published on: 29 April 2016
- Published on: 29 April 2016Authors' replyShow More
Dear Editor
In his letter, Dr Devoy is questioning the strength of the conclusion in our publication regarding the clinical efficacy of salmeterol on dyspnea, quality of life and reductions of exacerbations. We had stated that the effects with long-acting ß2-adrenergic bronchodilators on COPD exacerbations and on other health outcomes has provided inconsistent results [1] We note that Dr Devoy’s argument is mo...
Conflict of Interest:
None declared. - Published on: 29 April 2016Reflecting the balance of evidence for salmeterol in COPDShow More
Dear Editor
We would like to comment on strength of conclusions of the recent publication by Dr Brusasco et al,[1] particularly that no consideration is given to how the results compare to the balance of evidence that exists.
The paper’s conclusions imply superior efficacy of tiotropium over salmeterol in patients with COPD by emphasising endpoints in which tiotropium shows a difference compar...
Conflict of Interest:
None declared.